Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Ophthalmology
•
Uveitis and Ocular Immunology
What is your preferred regimen for treating recalcitrant and recurrent macula-threatening ocular toxoplasmosis?
Related Questions
Is it safe to continue azathioprine in a patient with severe bilateral panuveitis (thought to be related to sarcoidosis) and benign ethnic neutropenia, given worsening neutropenia since starting the medication, or should an alternative immunosuppressive agent be considered?
How do you approach perioperative steroids for a quiescent uveitis patient undergoing cataract surgery?
How do you manage Cancer-Associated Retinopathy (CAR) in a patient who doesn’t have a known cancer diagnosis, given the difficulty in finding the underlying cancer and the risks of using immunosuppressive treatments to preserve vision?
How do you differentiate between ocular involvement due to active tuberculosis versus latent infection in a patient with uveitis and suspected tuberculosis?
How do you decide between initiating systemic immunotherapy versus local treatment for uveitis with associated HLA-B27 and spondyloarthropathy?
How would you approach the management of dry corneal melt in a patient requiring high dose systemic steroids and no apparent underlying systemic autoimmune disease?
How do you approach the management of bilateral non-infectious uveitis in the pediatric population?
Would you consider using a JAK inhibitor for a patient with RA associated scleritis?
How do you manage checkpoint inhibitor-associated Vogt-Koyanagi-Harada (VKH) disease in patients who have poorly controlled diabetes?
When would you consider discontinuing immunosuppressive treatment in a quiescent uveitis patient without systemic manifestations of inflammation?
